A phase IIa trial of durvalumab in combination with tumor-infiltrating lymphocytes in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Trial Profile

A phase IIa trial of durvalumab in combination with tumor-infiltrating lymphocytes in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Durvalumab (Primary) ; LN 145 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 01 Jun 2017 According to a Lion Biotechnologies, first patient has been dosed.
    • 01 May 2017 Status changed from planning to recruiting, according to a Lion Biotechnologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top